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Abstract  
Breast cancer is the most commonly diagnosed form of cancer in Canadian women. Cancer 
treatments such as endocrine therapy, radiation therapy, and chemotherapy are often associated 
with pervasive, negative side effects. One of the most prevalent barriers to resuming normal 
functioning following the completion of treatment is known as cancer-related cognitive 
dysfunction (CRCD). However, the factors that may influence the development of these 
cognitive impairments remain unclear. A potential underlying mechanism of CRCD that has not 
been well-studied is sleep quality. The present study sought to determine whether a patient’s 
sleep quality prior to treatment is indicative of cognitive functioning four months following the 
initiation of treatment in a sample of 32 women with breast cancer, using both subjective and 
objective measures. We found that all patients experienced worsened cognitive function, sleep, 
and mood disturbance at four months on subjective measures compared to baseline. Our findings 
may indicate that women with insomnia symptoms prior to diagnosis may begin treatment with 
poorer cognition and thus be at a higher risk for further cognitive deterioration. Moreover, 
women that do not exhibit symptoms of insomnia prior to beginning treatment may have a buffer 
against a decline in cognition. Participants with insomnia symptoms at baseline may also be at an 
increased risk for worsened mood disturbance as their treatment regimen proceeds. Future 
research should examine the changes in cognition, sleep, and mood disturbance with longer 
follow ups and investigate whether sleep quality mediates or moderates the relationship between 
cancer treatment and CRCD.  
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Background 
Breast cancer is the most commonly diagnosed form of cancer in Canadian women, with 
one in nine Canadian females receiving a breast cancer diagnosis in their lifetime (Canadian 
Cancer Society, 2015). As of 2015, this disease is the second leading cause of death in females 
(Canadian Cancer Society, 2015). Fortunately, due to advances in cancer detection and treatment 
(Frank, Vance, Triebel, & Meneses, 2015; Tao, Visvanathan, & Wolff, 2015), women are now 
more likely to survive their diagnosis. However, cancer treatments such as endocrine therapy, 
radiation therapy, and chemotherapy are often associated with pervasive side effects that can be 
debilitating. 
Cancer-Related Cognitive Dysfunction  
One of the most prevalent barriers to resuming normal functioning following the 
completion of treatment is known as cancer-related cognitive dysfunction (CRCD). These 
impairments may include attention deficits, memory loss, and impairments in executive 
functioning, visuospatial skill, psychomotor speed, short term memory, and verbal memory 
(word retrieval and recall) (Bernstein, McCreath, Komeylian, Rich, 2017; Kanaskie & Loeb, 
2015; Miao et al., 2016; Tao, Visvanathan, & Wolff, 2015). CRCD is one of the most frequently 
reported symptoms by patients, with as many as 75% of individuals endorsing some level of 
impairment during treatment (Boykoff, Moieni, & Subramanian, 2009; Kanaskie & Loeb, 2015; 
Tannock, Ahles, Ganz, van Dam, 2004). Furthermore, approximately 35% of patients continue to 
experience difficulties in cognitive domains, with some studies suggesting that these 
impairments may persist for at least 5-10 years post-treatment (Amidi et al., 2015; de Ruiter et 
al., 2011).  
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Unfortunately, physicians rarely discuss the potential for changes in cognition prior to 
initiating cancer treatment (Kanaskie & Loeb, 2015). These impairments can make it difficult for 
women to resume their daily routines, including work (Boykoff et al., 2009). Breast cancer 
survivors living with CRCD often face difficulty performing effectively in the workplace, with 
some women taking leaves of absence or even resorting to early retirement (Boykoff et al., 2009; 
Munir, Burrows, Yarker, Kalawsky, & Bains, 2010). Self-report measures and interviews with 
breast cancer survivors post-adjuvant treatment regarding their perceived cognitive impairments 
reveal that CRCD is one of their most distressing symptoms (Boykoff et al., 2009; Kanaskie & 
Loeb, 2015; Von Ah et al., 2013). CRCD has the potential to cause or exacerbate emotional and 
psychological distress, severely impacting quality of life (Downie et al., 2006; Mitchell, 2007).  
Measuring Cognitive Impairments 
It is important to consider subjective in addition to objective measures of cognitive 
functioning, since self-report may be the primary indicator of cognitive impairment in cancer 
patients.  
Subjective cognitive assessment. Indices of subjective cognitive function can provide 
information that is not captured in objective assessments, such as personal experience of 
cognitive change following treatment, and how patients cope with these impairments (Kanaskie 
& Loeb, 2015). Kanaskie and Loeb (2015) interviewed a sample of seven women that had been 
treated with chemotherapy for breast cancer within the past twelve months regarding various 
domains of cognitive function (executive function, attention, concentration, memory and recall, 
and processing). Participants in this study were interviewed once per month for two months and 
kept a journal to note any experiences with cognitive difficulty during the time between 
interviews. Women in this study noted that they began experiencing cognitive changes during, as 
3 
 
well as months after beginning chemotherapy (Kanaskie & Loeb, 2015). Word retrieval was the 
most commonly described problem expressed by participants. Women also expressed severe 
difficulty with short-term memory, concentration, organization, and mental fatigue.  
In a similar study, 22 breast cancer survivors that had completed chemotherapy a 
minimum of 12 months prior to recruitment were interviewed to assess perceived cognitive 
impairment (Von Ah et al., 2013). All women in this study reported problems with their memory 
since beginning treatment. Specifically, the common domains that exhibited impairment were 
short-term and long-term memory, processing speed, attention and concentration, language, and 
executive function. Moreover, women reported that their biggest concerns were related to their 
cognitive impairments. In a later study, Von Ah and Tallman (2015) examined the relationship 
between subjective cognitive impairment [Functional Assessment of Cancer Therapy-Cognitive 
scale (FACT-Cog)] and objective cognitive performance (neuropsychological tests) in women 
previously treated for breast cancer. The results of this study were novel, as it was one of the first 
to show a correlation between FACT-Cog scores and objective measures of immediate and 
delayed verbal memory, as well as executive function. Therefore, subjective measures of 
cognitive functioning may be an efficient way to identify cognitive impairments in breast cancer 
survivors (Von Ah & Tallman, 2015).  
Though the results of these studies examining subjective cognitive impairment provide 
insight into women’s perceived cognitive impairments, it is important to acknowledge their 
limitations. First, cognitive impairment as measured by subjective tests of cognitive function, 
does not always correlate with performance on objective measures (Von Ah et al., 2013).  
Second, these studies exclusively examined subjective cognitive functioning in women that had 
completed treatment up to a year or more prior to being recruited. This may have been 
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problematic because patients were often required to comment retrospectively about their 
perceived cognitive impairments, which is not always reliable.  
Objective cognitive assessment. Cognitive impairments have also been observed in 
women receiving treatment for breast cancer by administering a series of objective 
neurocognitive measures. These studies have consistently shown that patients receiving various 
treatment regimens exhibit impairments in areas such as learning and memory, visual, verbal, 
and working memory, as well as processing speed and executive function (Meattini et al., 2017).  
Particularly, many studies have examined the impact of adjuvant treatment 
(chemotherapy and endocrine therapy) on cognitive functioning by administering neurocognitive 
measures. One study compared neurocognitive test scores of 31 breast cancer patients 
undergoing adjuvant chemotherapy treatment, 40 breast cancer survivors two years adjuvant 
post-treatment, and 36 healthy controls. Both current and post-treatment groups experienced 
significantly more neurocognitive impairments than women in the healthy control group 
(Brezden et al., 2000). Corroborating these findings, patients receiving adjuvant therapy have 
performed worse on visual and verbal working memory tasks when compared with patients 
affected by ductal carcinoma not receiving adjuvant treatment (Bender et al., 2006). 
Additionally, a study examining cognitive function in 120 early-stage breast cancer patients 
receiving chemotherapy or tamoxifen provided evidence to support that patients treated with 
either chemotherapy or endocrine therapy are three times more likely than healthy controls to 
experience impairments six months following treatment (Debess, Riis, Engebjerb, Ewertz, 2010).  
Prospective studies examining the impact of treatment on cognition have revealed results 
that support previous findings. These studies provide evidence for declines in areas such as 
processing speed, verbal ability, and motor performance specific to women treated with adjuvant 
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therapy (Ahles et al., 2010; Tager et al., 2010). Many of these studies have consistently found 
that women treated with chemotherapy for breast cancer exhibit more cognitive impairment 
compared to other treatments (Ahles et al., 2010; Jansen, Cooper, Dodd, & Miaskowski, 2011; 
Tager et al., 2010). One prospective study compared the effects of treatment on cognitive 
function by recruiting 41 women receiving chemotherapy, and 40 women receiving radiation 
therapy in the absence of other treatment (Quesnel, Savard, & Ivers, 2009). Neurocognitive 
measures were administered at baseline, post-treatment, and at 3-month follow-up, revealing that 
women receiving chemotherapy exhibited more cognitive impairment than women receiving 
radiation therapy (Quesnel et al., 2009). Specifically, chemotherapy appeared to have a negative 
effect on verbal fluency. Similarly, Jansen et al. (2011) administered a battery of 
neuropsychological tests to a sample of 91 women at baseline in addition to three assessments 
following the initiation of chemotherapy. Consistent with previous findings (Bender et al., 2006; 
Collins et al., 2009), women in this study experienced a significant decline in areas such as 
attention, visuospatial skill, delayed memory, as well as motor function throughout the course of 
treatment.  
However, there has also been evidence to suggest that neurocognitive impairments also 
exist in patients receiving endocrine treatment in the absence of chemotherapy. Palmer, Trotter, 
Joy, and Carlson (2008) compared 35 women receiving tamoxifen to healthy controls and found 
that patients being treated with tamoxifen showed impairments in areas similar to patients treated 
with adjuvant or chemotherapy treatment, such as visual and verbal memory, verbal fluency, 
visual-spatial ability, and processing speed. Despite the conflicting findings in the literature 
regarding the effects of specific treatment on cognition, it is clear that women receiving 
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treatment for breast cancer are at risk for developing cognitive impairments, regardless of 
treatment regimen.  
Previous studies have been effective in identifying neurocognitive impairments in women 
diagnosed with breast cancer. Prospective studies are especially beneficial, as they allow 
researchers to observe changes in cognition throughout the course of treatment. However, similar 
to subjective studies, objective studies examining cognitive impairments in this population also 
have limitations. Many objective studies administer different neurocognitive measures, which 
can lead to conflicting results between studies. To provide reliable findings, these studies should 
remain consistent with the measures that are administered, as some neurocognitive measures are 
more sensitive than others. Additionally, it is important to note that many of these studies have 
not detected changes in objective cognitive functioning until at least six months following 
treatment onset (Debess et al., 2010; Quesnel et al., 2009), whereas studies measuring cognitive 
impairment subjectively have concluded that women report changes in their cognitive 
functioning much earlier in their treatment trajectory (Kanaskie & Loeb, 2015; Von Ah et al., 
2013).  
Theories of Cancer-Related Cognitive Dysfunction  
Though previous studies have provided comprehensive evidence for the development of 
CRCD after a woman begins treatment for breast cancer, the underlying mechanisms are still 
unclear. Based on previous findings, it is clear that these cognitive impairments are not isolated 
to a single treatment, and that there are still many conflicting findings. As a result, there have 
been several theories posited to explain the development of CRCD, as well as the mechanisms 
underlying CRCD.  
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Genetics. Some studies have suggested that genetic factors may influence the 
development of CRCD (Janelsins, Kesler, Ahles, Morrow, 2014). For instance, patients 
previously diagnosed with cancer carrying an E4 allele are at a greater risk for developing CRCD 
(Ahles et al., 2003; Ahles et al., 2010). These individuals scored lower on a variety of cognitive 
measures, such as visual memory, spatial ability, and executive function, compared to those 
without this allele (Ahles et al., 2003). Further, Ahles et al. (2010) found that individuals with 
lower pre-treatment cognitive capacity were at a greater risk for decline in processing speed post-
chemotherapy treatment.  
Neuroanatomy. There are substantial changes in neuroanatomy associated with 
cognitive impairment in patients treated with chemotherapy. Using magnetic resonance diffusion 
tensor imaging, Deprez et al. (2011) observed significantly lower white matter integrity in the 
temporal and parietal tracts in 17 women treated with chemotherapy, which were compared to 18 
healthy controls and 10 non-chemotherapy treated breast cancer patients. Furthermore, tests of 
attention and processing speed in this sample were correlated with parietal and temporal white 
matter integrity (Deprez et al., 2011). In a similar study, McDonald et al. (2013) compared MRI 
scans of women being treated for breast cancer with and without chemotherapy, as well as 
healthy controls. Significant reductions in frontal grey matter were observed in patients being 
treated with chemotherapy approximately six months following baseline assessment (McDonald 
et al., 2013). These results suggest that the alterations in these brain regions are specific to 
chemotherapy treatment, and are significant since the frontal regions of the brain are important 
for executive function and memory processes (Deprez et al., 2011; McDonald et al., 2013). 
Immune response. Investigators have also suggested that inflammation accompanying a 
patient’s immune response may precipitate or promote the development of CRCD. Cytokines are 
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commonly recognized for their role in regulating inflammation; however, they are also central in 
the maintenance of cell functioning and repairing neurotransmitters, all of which are important 
for normal cognitive function (Wilson, Finch, & Cohen, 2002). Many neurodegenerative 
disorders (such as Alzheimer’s disease and multiple sclerosis) have been associated with the 
deregulation of cytokines (Tonelli, Postolache, Sternberg, 2005).  
The relationship between cytokines and cognitive function is evident in cancer patients 
receiving immunotherapy. Researchers have suggested that the deregulation of cytokines 
experienced by patients receiving immunotherapy is associated with symptoms such as fatigue 
and cognitive disruption (Scheibel, Valentine, O’Brien, & Meyers, 2004). Moreover, 
longitudinal studies examining the effect of particular immunotherapies on cognition have 
revealed that patients experience deficits in cognitive abilities such as processing speed, 
executive function, spatial ability, and reaction time (Capuron, Ravaud, & Dantzer, 2001; 
Scheibel et al., 2004). Though there have not been any studies examining the association 
between cytokines, cancer treatment, and cognition, researchers have speculated about these 
relationships. Higher levels of inflammatory cytokines have been observed in patients treated 
with chemotherapy, leading researchers to suggest that higher levels of inflammatory cytokines 
are associated with cognitive dysfunction (Ahles & Saykin, 2007; Cleeland et al., 2003). 
Demographic and lifestyle factors. Many studies examining the impact of cancer 
treatment on cognitive function have consisted of samples of women from an older population. 
The mean age of women recruited in these studies are usually between 45-60 years of age (Ahles 
et al., 2010; Jansen et al., 2011; Palmer et al., 2008; Quesnel et al., 2009). One study examining 
the impact of age on cognitive functioning in women receiving adjuvant treatment for breast 
cancer revealed that post-treatment decline in processing speed was associated with age and pre-
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treatment cognitive reserve, defined as an individual’s innate and developed cognitive capacity 
(Ahles et al., 2010). Specifically, patients receiving chemotherapy who were older and had a 
lower pre-treatment cognitive reserve performed worse than patients who did not receive 
chemotherapy, as well as healthy controls, on measures of processing speed. These findings 
suggest that older patients exhibiting a lower pre-treatment cognitive reserve may be at a higher 
risk for developing problems with processing speed when receiving chemotherapy as part of 
their treatment regimen. Despite age being the most common explanation for cognitive decline, 
previous studies have also suggested that both younger and older patients experience CRCD 
(Janelsins et al., 2014).  
Lifestyle factors such as physical activity, obesity, and sleep have also been associated 
with cognitive functioning in patients that have completed treatment for breast cancer. Hartman, 
Marinac, Natarajan, and Patterson (2015) assessed 136 post-menopausal breast cancer survivors 
on measures of neuropsychological functioning, height, weight, physical activity (Global 
Physical Activity Questionnaire), and sleep (duration per night). Women reporting higher levels 
of physical activity performed significantly better than women reporting lower levels of physical 
activity on measures of attention and executive functioning. Additionally, women who were 
obese were three times more likely to exhibit impairments on domains of processing speed than 
those who were not. Finally, women reporting more hours of sleep per night correlated with 
improved performance in verbal functioning. Unfortunately, this study was primarily based on 
women’s self-report for physical activity and sleep measures. Moreover, the investigators only 
included one question about sleep, which was regarding the duration of sleep obtained per night. 
Sleep as a Potential Mechanism of CRCD 
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Although there is evidence that women undergoing treatment for breast cancer exhibit 
CRCD, the factors that may influence the development of these cognitive impairments remain 
unclear. According to the International Cognition and Cancer Task Force, studies should focus 
on potential mechanisms that may underlie such impairments (Wefel, Vardy, Ahles, & Schagen, 
2011). A potential underlying aspect of CRCD that has not been well-studied is sleep quality. 
The quality of sleep before, during, and after cancer treatment may influence the development of 
CRCD. 
Cancer Treatment and Sleep Disturbances 
In addition to CRCD, sleep disturbances are among the most highly reported side effects 
experienced by patients being treated for cancer, with as many as 30-50% of patients reporting 
sleep difficulties (Savard, Ivers, Villa, Caplette-Gingras, Morin, 2011). The prevalence of sleep 
disturbance in individuals diagnosed with cancer is two to three times greater than the general 
population (Berger et al., 2005). It appears that treatment-related sleep difficulties occur across 
various stages of cancer, with as many as 75% of early-stage patients and 72% of advanced stage 
patients reporting sleep difficulties (Fiorentino & Ancoli-Israel, 2006; Sela, Watanabe, & 
Nekolaichuk, 2005; Savard et al., 2011). Patients have reported that sleep disturbances are 
among their most distressing symptoms (Liu et al., 2012), and poor sleep can cause, and/or 
exacerbate, other medical and psychological conditions. 
Causes of Sleep Disturbances 
The disturbances in sleep that patients experience throughout the night can be due to 
physical side effects of treatment (Kim, McDermott, Barsevick, 2014; Lee, Cho, Miaskowski, & 
Dodd, 2004). For instance, one of the most prevalent side effects experienced by breast cancer 
patients receiving endocrine therapy is hot flashes (Engstrom, 2008; Savard, Hervouet, & Ivers, 
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2013), which can negatively impact a patients’ sleep (Downie et al., 2006; Savard et al., 2013). 
In 2006, Downie et al. employed a variety of subjective and objective measures to collect data 
regarding the relationship between fatigue, menopausal symptoms, and cognitive performance in 
twenty-one women receiving adjuvant chemotherapy for breast cancer. Approximately half of 
their sample was awakened by hot flashes during the night, leading them to experience fatigue 
during the day that impacted their daily functioning (Downie et al., 2006).  
In addition to hot flashes, patients experience pain that is cancer-related and treatment-
related. Pain is one of the most common attributions to insomnia as identified by patients 
diagnosed with cancer (Davidson, MacLean, Brundage, & Schulze, 2002). Approximately 40-
55% of early-stage patients and 60-95% at advanced stages report cancer-related pain (Davidson 
et al., 2002; Sela et al., 2005). Increases in pain are positively correlated with sleep disturbance, 
with as many as 59% of patients attending pain clinics reporting sleep disturbances (Lee, Cho, 
Miaskowski, 2004; Sela et al., 2005). Lewin and Dahl (1999) suggest that the relationship 
between pain and sleep disturbance operates similar to a feedback-loop, such that poor sleep 
impairs the body’s ability to repair tissue, which increases pain. The increased pain further 
disrupts sleep and this poor sleep leads to a reduction in a patients’ emotional capacity to 
successfully manage pain, increasing pain perception, thus creating a continuous cycle of poor 
sleep and pain (Lewin & Dahl, 1999). Another explanation underlying the relationship between 
sleep disturbance and pain involves opioid use. To help control pain, patients diagnosed with 
cancer are often prescribed opioids; however, opioids decrease rapid eye movement and slow-
wave sleep and may actually contribute to sleep disturbances experienced by these patients 
(Dimsdale, Norman, DeJardin, & Wallace, 2007).  
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Another potential underlying mechanism of sleep disturbances that warrants attention are 
the psychological side effects experienced by patients undergoing treatment for cancer. Previous 
studies have reported that many of the difficulties falling and staying asleep that patients 
experience throughout the night are due to psychological factors such as anxiety and depression 
(Clevenger et al., 2013; Downie et al., 2006; Trill, 2013). One study examined the contribution 
of depression and anxiety to sleep disturbance in women with ovarian cancer during the first year 
of diagnosis. Women in this study had higher depressive symptoms, which was associated with 
greater sleep disturbance (Clevenger et al., 2013). In a similar study, the relationship between 
sleep disturbance (measured by the Athens Sleep Insomnia Scale) and psychological distress 
(measured by the Hospital Anxiety and Depression Scale) was examined in a sample of 50 
patients diagnosed with lung cancer (Nishiura, Tamura, Nagai, & Matsushima, 2015). In this 
sample 56% of patients experienced sleep disturbance. Moreover, patients with sleep disturbance 
had higher scores on the HADS, and all patients with sleep disturbance met criteria for 
subclinical or clinically significant depression/anxiety (Nishiura et al., 2015). It is important to 
consider anxiety and depression as an underlying contributor to sleep disturbance, as these 
psychological comorbidities often appear at the outset of a cancer diagnosis, and can persist even 
after a patient is cancer-free (Trill, 2013). 
Objective Sleep Disturbance 
The most common method of measuring objective sleep in patients diagnosed with 
cancer has been through actigraphy. When compared to healthy controls, cancer patients have 
consistently exhibited less contrast between day and night activity, which is indicative of 
circadian rhythm disruption (Fernandes et al., 2006; Levin et al., 2005). In one study, patients 
diagnosed with stage I-III breast cancer receiving chemotherapy-based treatment wore a wrist 
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actigraph for 72 hours prior to the administration of treatment, and for three weeks during cycles 
one and four of treatment (Savard et al., 2009). Disruptions of sleep-wake rhythms were 
observed following the first administration of chemotherapy, with progressively worse 
disruptions occurring with each consecutive cycle of chemotherapy.  
Similarly, Liu et al. (2012) recruited 97 women scheduled to receive chemotherapy for 
breast cancer to examine the relationship between fatigue and sleep by administering objective 
and subjective measurements of sleep at baseline, and for three weeks during both cycles one and 
four of treatment. These measures were obtained using actigraphy, as well as the Pittsburgh 
Sleep Quality Index and the Multidimensional Fatigue Symptom Inventory-Short Form. Patients 
experienced worsened fatigue, and spent more time sleeping during the night and day when 
undergoing chemotherapy (Liu et al., 2012).  
Patients undergoing other methods of treatment besides chemotherapy also experience 
sleep disturbance. Using measures of objective and subjective sleep disturbance, Dhruva et al. 
(2012) carried out a longitudinal study examining sleep disturbance prior to, during, and 
following radiation therapy in 73 women diagnosed with breast cancer. Upon beginning RT, the 
majority of women experienced a high number of night time awakenings which was classified as 
abnormal. Additionally, patients were awake for 11% of the time following sleep onset, which 
exceeds the cut-off of 10% for healthy adults (Dhruva et al., 2012).  
Subjective Sleep Disturbance 
It is also important to consider a patient’s perception of their sleep quality. Self-report 
measures have revealed that patients being treated for various types of cancer experience 
difficulties with sleep. A cross-sectional survey examining sleep disturbance in a heterogeneous 
sample of 1000 patients revealed that of all cancer types included in the sample, women with 
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breast cancer present the highest prevalence of sleep disturbances (Davidson et al., 2002). 
Additionally, 76% of this sample reported experiencing multiple awakenings throughout the 
night, with nearly 31% meeting the criteria for insomnia disorder. Moreover, patients treated 
with radiation therapy, chemotherapy, or surgery in the past six months were more likely than 
those not treated in the past six months to report sleep problems, as well as excessive sleepiness, 
fatigue, and hypersomnolence (Davidson et al., 2002).  
Prospective longitudinal studies have also revealed that patients with cancer report sleep 
difficulties prior to, as well as throughout the course of their treatment (Savard et al., 2011). 
Savard et al. (2011) interviewed 962 patients diagnosed with cancer using an insomnia 
diagnostic interview at six time points over the course of eighteen months (including a baseline 
assessment). At baseline 31% of their sample exhibited symptoms of insomnia and 28% met 
diagnostic criteria for an insomnia syndrome. Patients with symptoms of insomnia at baseline 
were more likely to have insomnia eighteen months later. By the sixth assessment, 21% of their 
sample had insomnia syndrome and 15% exhibited symptoms of insomnia. Of note, patients 
diagnosed with breast cancer exhibited the highest prevalence of insomnia throughout the study, 
with 42-69% of breast cancer patients meeting criteria for insomnia. Based on these findings, it 
may also be imperative to consider whether patients experience symptoms of insomnia at 
baseline, as these patients may be at further risk for developing an insomnia disorder as their 
treatment regimen proceeds.   
The Impact of Poor Sleep on Cognition  
Even partial sleep loss accumulated over a few days can have negative impacts on a 
variety of cognitive functions such as attention, memory, executive function, and behavioural 
alertness, all of which are imperative for proper daytime functioning (Gobin, Banks, Fins, & 
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Tartar, 2015; Van Dongen, Maislin, Mullington, & Dinges, 2003). Moreover, individuals that 
repeatedly obtain less than 7 hours of sleep per night demonstrate increased lapses of attention, 
and are at a higher risk for developing cognitive dysfunction (Belenky et al., 2013; Van Dongen 
et al., 2003). Van Dongen et al. (2003) randomly assigned 48 healthy adults to one of three 
varying time-in-bed conditions (eight hours, six hours, and four hours per night) and assessed 
their performance on neurocognitive measures.  This study revealed impairments in working 
memory performance that were dependent on the amount of time-in-bed permitted. Participants 
in the eight-hour time-in-bed group performed best on the task, and those in the four-hour time-
in-bed group performed worst on the task (Van Dongen et al., 2003). Additionally, it was 
apparent that individuals in this study had a tendency to overestimate their performance on tasks 
that required vigilance, and underestimated the impact that sleep restriction had on their 
cognitive abilities (Van Dongen et al., 2003). This is especially of concern, as individuals may 
attempt every-day tasks that require attention and reactivity (such as operating a motor-vehicle) 
without realizing their level of impairment.  
Though these studies effectively demonstrate the short-term effects of sleep-related 
cognitive impairment, it is important to consider the long-term consequences of sleep disruption 
on cognitive functioning. In humans, prolonged sleep disruption can lead to the inability to detect 
changes in the surrounding environment, slower reaction times, and, in severe cases, 
hallucinations (Alkadhi et al., 2013; Reynolds et al., 2013). Additionally, chronic sleep 
disruption may negatively impact the functioning of the prefrontal cortex, impairing an 
individual’s attention and ability to make executive decisions (Boonstra et al., 2007). The effects 
of long-term sleep disruption have been linked to neurodegenerative diseases such as dementia 
and Alzheimer’s disease (Xie et al., 2013). This is explained by the accumulation of β-amyloid 
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that destroys neurons as a result of chronic sleep loss (Xie et al., 2013). The potential impacts of 
poor sleep are vast and have the potential for life-long consequences.  
Sleep Disturbance and CRCD in Women with Breast Cancer 
Compared to other cancer types, women with breast cancer are the most at risk for sleep 
disturbance (Savard et al., 2009; Servaes & Bleijenberg, 2002). However, the impact that poor 
sleep quality has on cognition in breast cancer patients receiving treatment has not been studied. 
The quality of sleep that a patient experiences before, as well as throughout the duration of their 
treatment may have the potential to contribute to the development of CRCD, as well as further 
exacerbate symptoms of cognitive impairment. Since previous studies have shown that cancer 
treatments can negatively impact sleep, poor sleep may further increase an individual’s risk of 
developing CRCD (Servaes & Bleijenberg, 2002). Addressing the underlying causes of CRCD is 
crucial in order to develop effective prevention, early intervention, and treatment regimens.  
Research that attempts to delineate the underlying causes of cognitive dysfunction in 
cancer patients has been growing. However, many of these studies have focused solely on 
cognitive impairments that arise during treatment or post-treatment, or have only used self-report 
measures of sleep and cognition (Bower, 2008; Hutchinson, Hosking, Kichenadasse, Mattiske, & 
Wilson, 2012; Von Ah et al., 2013). The present study sought to determine whether a patient’s 
sleep at baseline (prior to beginning treatment) is indicative of cognitive functioning four months 
following the initiation of treatment in a sample of women with breast cancer using both 
subjective and objective measures of cognitive functioning and sleep to better understand the 
changes in cognitive functioning during the early stages of treatment.  
In conducting this research, we answered the following questions in a sample of newly 
diagnosed women with breast cancer: (1) Is there a change in objective and subjective sleep, 
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cognitive functioning, and mood disturbance from pre-treatment to four months in women with 
and without insomnia symptoms (2) Is change in sleep associated with cognitive impairment and 
psychological disorders? 
We hypothesized that (1) patients will exhibit worse cognitive function, sleep, and mood 
disturbance on subjective measures, and not on objective measures, at four months compared to 
baseline measures, and (2) that poor sleep is associated with more subjective cognitive 
impairment at four months, as well as higher scores on measures of anxiety and depression.  
Methods 
Participants 
Participants were recruited from the Dr. H. Bliss Murphy Cancer Center in St. John’s, 
Newfoundland. Patients were informed of the study by their treating oncologist during their 
appointment at the Cancer Centre. Patients were eligible for the study if they had recently 
received a diagnosis of stage I-III breast cancer, and were scheduled to receive chemotherapy, 
hormonal therapy, or radiation therapy. Patients were ineligible for the study if they had been 
previously treated for cancer or were presently undergoing cancer treatment. Moreover, patients 
were ineligible if they had a sleep disorder besides insomnia that was not adequately treated, a 
psychological disorder that was not currently stable or would impair their ability to participate, 
or if they scored lower than 24 on the Mini-Mental State Examination (suggesting the presence 
of a severe cognitive impairment). Patients were also ineligible to participate if they had an 
existing medical condition that would impair their cognition and/or ability to participate, such as 
Parkinson’s disease, or Alzheimer’s Disease, or previous history of a stroke. 
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Procedure 
Recruitment. Treating oncologists in the Dr. H. Bliss Murphy Cancer Centre cancer 
center identified eligible participants by examining their clinical charts. At the time of the 
patients’ appointment, the treating oncologist informed them of the study by providing a brief 
description, and asked them if they would like to speak with a research assistant (RA) about the 
study. If the patient was agreeable, the RA met with the patient for approximately five minutes to 
provide the patient with information about the study. The RA described the study to the patient, 
including background information, objectives, a brief description of the assessment types, and 
frequency of assessment. If the patient was interested in participating, the RA obtained the 
patients’ contact information. If the patient preferred to speak with someone at a later time, they 
were provided with an introduction letter which included a description of the study, and 
information to contact the RA or the principal investigator. 
Screening. Once informed consent was obtained, the RA screened the participant for any 
sleep, psychological, or medical complications that would impair their ability to participate in the 
study. This included administering the Mini-Mental State Exam (MMSE), and a study developed 
sleep, psychological, and medical history screening questionnaire.   
Baseline and Four-Month Follow-up Assessments. Informed consent to participate in 
the study was obtained at the beginning of the baseline assessment. Baseline and four-month 
follow-up assessments followed the same procedure and were scheduled at the convenience of 
the participants. Assessments consisted of cognitive assessments, self-report measures, as well as 
wearing an Actigraph and completing a Sleep Diary for one week (see measures). The total time 
to complete each assessment was approximately 45-60 minutes. At the end of each assessment, 
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participants were given the Actigraph and Sleep Diary, as well as a postage-paid envelope to 
return these items by mail.  
These assessments were completed in-person or by telehealth at their local healthcare 
centre to complete the assessment. If a participant completed an assessment via Telehealth, the 
Actigraph, Sleep Diary, as well as the questionnaires were mailed to them with a postage-paid 
envelope to return the materials in following the Telehealth assessment. Participants were asked 
to begin wearing the Actigraph and begin the Sleep Diary as soon as they received it in the mail, 
and to complete the questionnaires at the earliest possible opportunity.  
Measures 
To provide an objective assessment of cognition, we included the neurocognitive 
measures recommended by the International Cognition and Cancer Task Force (Wefel et al., 
2011).  
Screening and demographics. Demographics information such as sex, age, ethnicity, 
marital status, and employment status was collected from all participants. 
The sleep, psychological, and medical history screening questionnaire obtained 
information such as cancer type, diagnosis date, treatment date, and type of treatment received, 
sleep and psychiatric history, and current medication use.  
To determine whether a participant exhibited a cognitive impairment that would impair 
their ability to participate in the study, the MMSE was administered. A score lower than 24 on 
the MMSE indicates a severe cognitive impairment. The MMSE demonstrates good reliability 
and construct validity when compared against gold standards that identify and measure cognitive 
impairment (Tombaugh & McIntyre, 1992).  
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Subjective Neurocognitive Assessments 
The Functional Assessment of Cancer Therapy – Cognitive Function Version 3 
(FACT-Cog V3). The FACT-Cog V3 is a 37-item self-report questionnaire consisting of four 
cognitive subscales: perceived cognitive impairments, impact on quality of life, comments from 
others, and perceived cognitive abilities (Jacobs, Jacobsen, Booth-Jones, Wagner, & Anasetti, 
2007; Wagner, Sweet, Butt, Lai, & Cella, 2009). This questionnaire requires participants to 
reflect on these items regarding the past seven days. Responses may range from 0 (never) to 4 
(several times a day). Perceived cognitive impairment and impact on quality of life subscales are 
reverse-scored, with higher scores indicating better cognitive functioning and that cognitive 
functioning has more of an impact on quality of life, respectively. Higher scores on the perceived 
cognitive ability subscale indicate better cognitive functioning.  
Objective Neurocognitive Assessment 
The Hopkins Verbal Learning Test-Revised (HVLT-R). The HVLT-R assesses verbal 
learning and memory, including immediate and delayed recall, as well as delayed recognition. 
Each version of the HVLT-R consists of a list of 12 nouns with four words drawn from each of 
three semantic categories (Brandt & Benedict, 2001). The HVLT-R exhibits high test-retest 
reliability, as well as construct, concurrent, and discriminant validity (Brandt & Benedict, 2001; 
Brandt, 1991). HVLT-R test booklets one and two were used for baseline and 4-month follow-up 
assessments, respectively. Higher scores indicate better cognitive functioning. 
Letter-Number Sequencing (LNS). LNS is a supplemental subtest obtained from the 
Weschler Adult Intelligence Scale. This task requires participants to recall a series of numbers 
and letters by stating the numbers first, then the letters, in ascending order. LNS is a measure of 
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working memory, attention, and mental control (Wechsler, 2008). Higher scores indicate better 
cognitive functioning.  
Subjective Sleep 
Insomnia Severity Index. The Insomnia Severity Index (ISI) is a patient-reported 
outcome that assesses the impact that insomnia has on daytime functioning, as well as the 
amount of associated distress (Bastien, Vallieres, & Morin, 2001). Items are scored on a five-
point scale ranging from 0 to 4 with higher scores representing more severe insomnia symptoms. 
The cut-off scores are 0-6 (no clinically significant sleep difficulties, 7-14 (sleep difficulties 
require further investigation) and 15+ (clinically significant insomnia) (Bastien et al., 2001). The 
ISI has demonstrated internal consistency, reliability, construct validity, specificity and 
sensitivity in a representative sample of 1670 cancer patients (Savard et al., 2005).  
The Consensus Sleep Diary (CSD). A self-report measure of sleep which will be 
completed by participants for 7 consecutive days. Participants will report their sleep duration, 
perceived quality, and disruption. Sleep diaries are considered a reliable and valid patient self-
report of nightly insomnia symptoms (Carney et al., 2012). The CSD collects information such 
as total sleep time, sleep onset latency, wakefulness after initial sleep onset, total time spent in 
bed, and sleep quality/satisfaction (Carney et al., 2012).  
Objective Sleep Measure 
Actigraphy monitoring provided objective information regarding a participant’s sleep. An 
actigraph is a wrist-worn device similar to a watch that can record activity levels throughout the 
day and night. This information includes sleep efficiency, latency, total sleep time, as well as the 
frequency and number of awakenings. The type of actigraph that will be utilized in the present 
study is the Motionlogger, which is among the most accurate instruments for collecting objective 
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actigraphic data, having an approximate 90% accordance with polysomnography (Rupp & 
Balkin, 2011). 
Comorbid Symptom Outcomes 
The Hospital Anxiety and Depression Scale (HADS). The HADS is a 14-item, self-
rated instrument for anxiety (7 items) and depression (7 items) symptoms in the past week and 
has been extensively used in people with cancer (Bjelland, Dahl, Haug, & Neckelmann, 2002; 
Mitchell, Meader, & Symonds, 2010). The following cut-offs have been established: 0–7 not 
significant; 8–10 subclinical; and 11-21 clinically significant depression/anxiety.  
The Multidimensional Fatigue Inventory-Short Form (MFSI-SF). The MFSI-SF is a 
30 item self-report measure consisting of five subscales (general, emotional, physical, mental, 
and vigor) and a total fatigue score. Internal consistency ranges from 0.87 to 0.92 with test-retest 
reliabilities ranging from 0.51 to 0.70. The MFSI-SF has demonstrated appropriate convergent 
and discriminant validity (Stein, Jacobsen, Blanchard, & Thors, 2004).  
Statistical Methods 
Descriptive statistics were generated for demographic, disease stage, and treatment 
characteristics. Paired samples t-tests were used to compare those with and without insomnia 
symptoms at baseline to determine whether there were any differences between the groups in 
terms of demographics, cognitive functioning, and mood disturbance. 
Repeated measures Analysis of Variance (ANOVA) was used to assess change in 
subjective and objective cognitive functioning, sleep, and mood disturbance from pre-treatment 
to four months following the initiation of treatment. In this analysis, the between subjects factor 
was group (participants with insomnia symptoms and without insomnia symptoms), and the 
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within subjects factor was time (pre-treatment and four months following the initiation of 
treatment).  
Finally, change scores were calculated on the ISI, FACT-Cog V3, and HADS by 
subtracting the baseline scores from the four-month follow-up scores. Correlational analyses 
were used to determine whether change in insomnia severity was associated with change in 
cognitive impairment, anxiety, and depression. 
Results 
Demographics 
Thirty-eight women diagnosed with stage I-III breast cancer agreed to participate in this 
study. Of the 38 participants who consented to participate, 6 participants were lost-to-follow-up 
at 4-months. Health complications, inability to travel to the nearest telehealth location, and being 
too busy to commit to the study were the indicated reasons for withdrawal. Therefore, there were 
32 participants that completed a 4-month follow-up assessment. Only participants with complete 
data (baseline and four months) were included in the analysis. The age of the participants ranged 
from 38 to 80 (M = 59.47, SD = 10.36), with the majority of participants being married (81.3%). 
The mean years of education completed in this sample were 14.06 years, and the majority of the 
sample identified as retired (65.6%). (See Table 1 for demographic information).  
This sample was further divided into those with and without insomnia symptoms, which 
was determined by ISI score at baseline. An ISI score less than or equal to 7 represented no 
insomnia (N = 16), and a score greater than or equal to 8 was indicative of insomnia symptoms 
(N = 16). At baseline there were no significant differences between those with and without 
insomnia symptoms with respect to age, years of education completed, hours worked per week, 
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hours of physical activity per week, or number of caffeinated beverages consumed per day (see 
Table 1 for p values).  
Participants with and without insomnia symptoms at baseline were compared to 
determine whether there was a difference between the groups in terms of subjective cognitive 
functioning and mood disturbance. Participants with insomnia symptoms (M = 50.63, SD = 
11.00) scored lower on the perceived cognitive impairment subscale than those without insomnia 
symptoms (M = 58.89, SD = 11.08), t (1,30) = 2.118, p = .043. Participants with insomnia 
symptoms (M = 18.88, SD = 5.41) also scored lower on the perceived cognitive ability subscale 
at baseline compared to those without insomnia symptoms (M = 22.88, SD = 4.81), t (1,30) = 
2.208, p = .035. Additionally, participants without insomnia symptoms (M = 14.31, SD = 3.61) 
exhibited higher scores on the impact of cognitive impairment on quality of life subscale 
compared to those with insomnia symptoms (M = 10.38, SD = 5.01), t (1,30) = 2.552, p = .022. 
Participants with insomnia symptoms (M = 5.06, SD = 3.34) scored higher on the depression 
subscale of the HADS compared to those without insomnia symptoms (M = 2.19, SD = 2.64), t 
(1,30) = 2.704, p = .011. Participants with insomnia symptoms (M = 9.19, SD = 3.76) also scored 
higher on the anxiety subscale of the HADS compared to those without insomnia symptoms (M 
= 4.56, SD = 4.55), t (1,30) = 3.135, p = .004. Refer to Figure 1 and Figure 2 for baseline scores 
on subjective cognitive functioning and mood disturbance measures. 
Cognitive Functioning  
Subjective. When examining the perceived cognitive impairment subscale of the FACT-
Cog V3, a significant effect of time was observed, F (1,30) = 13.089, p = .001, η2 = .304. This 
indicates that both groups had significantly more perceived cognitive impairment four months 
following the initiation of treatment compared to baseline (refer to Figure 3). A significant effect 
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of time was also observed for the perceived cognitive ability subscale of the FACT-Cog V3, F 
(1,30) = 4.780, p = .037, η2 = .137, indicating that both groups perceived less cognitive ability 
four months following the start of treatment compared to baseline (refer to Figure 4). A 
significant effect of group was observed for the perceived impact that cognitive impairment has 
on quality of life subscale of the FACT-Cog V3, F (1,30) = 5.076, p = .032, η2 = .145. 
Participants without insomnia symptoms (M = 14.00, SE = .765) indicated that their cognitive 
impairment had more of an impact on their quality of life compared to those with insomnia 
symptoms (M = 11.56, SE = .765) (refer to Figure 5).   
Objective. There were no significant time or group differences observed on baseline to 
four-month follow-up for those with or without insomnia symptoms on the HVLT-R (including 
measures of total recall, delayed recall, retention, and recognition). There were also no 
significant time or group differences observed from baseline to four-month follow-up for those 
with or without insomnia symptoms on LNS scores. See Table 2 for objective cognitive measure 
values.  
Subjective Sleep Measures 
Consensus Sleep Diary. When examining the number of minutes awake after sleep 
onset, a significant effect of group was observed, F (1,28) = 7.551, p = .010, η2 = .212. 
Participants with insomnia symptoms (M = 44.90, SE = 5.764) spent more time awake after sleep 
onset than those without insomnia symptoms (M = 22.50, SE = 5.764) (refer to Figure 6). In 
terms of sleep efficiency, there was a significant effect of group, F (1,28) = 7.842, p = .009, η2 = 
.219. Participants without insomnia symptoms (M = 84.60, SD = 2.079) had better sleep 
efficiency than those with insomnia symptoms (M = 76.37, SD = 2.079) (refer to Figure 7). 
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Additionally, there was a significant interaction of group and time in terms of sleep efficiency, F 
(1,28) = 6.295, p = .018, η2 = .018.  
There was no significant main effect of group or time, and there was no significant 
interaction for sleep diary measures of sleep onset latency, number of awakenings, total sleep 
time, or time spent in bed.  
Insomnia Severity Index. A repeated measures ANOVA revealed a significant effect of 
time, F (1,30) = 9.789, p = .004, η2 = .246, indicating that both groups exhibited more symptoms 
of insomnia four months following the initiation of treatment compared to baseline. There was 
also a significant effect of group, F (1,30) = 44.352, p = .000. Participants with insomnia 
symptoms (M = 14.63, SE = .982) exhibited more symptoms of insomnia compared to those that 
did not have insomnia symptoms (M = 5.38, SE = .982) (refer to Figure 8).  
Mood Disturbance 
Hospital Anxiety and Depression Scale. A repeated measures ANOVA revealed a 
significant effect of time on the depression subscale of the HADS, F (1,30) = 8.236, p = .007, η2 
= .215. Both groups experienced more symptoms of depression four months following the start 
of treatment compared to baseline. Additionally, there was a significant effect of group for the 
depression subscale of the HADS, F (1,30) = 5.672, p = .024, η2 = .159, indicating that 
participants with insomnia symptoms (M = 5.66, SE = .798) exhibited more symptoms of 
depression than those without symptoms of insomnia (M = 2.97, SE = .798). There was no 
significant interaction of group x time (p = .698). See Figure 9 for details.  
There was a significant effect of group on the anxiety subscale of the HADS, F (1,30) = 
9.164, p = .005, η2 = .234, indicating that participants with insomnia symptoms (M = 8.25, SD = 
.854) exhibited more symptoms of anxiety compared to those without insomnia symptoms (M = 
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4.59, SD = .854). There was no significant effect of time (p = .110) or group x time interaction (p 
= .089). See Figure 10 for details.  
Associations between Change Scores  
When change in insomnia severity was correlated with change in cognitive impairment, 
anxiety, and depression, we found that change in insomnia severity was only associated with the 
perceived cognitive ability subscale of the FACT-Cog V3, r = -.391, p = 016. Increases in 
insomnia symptoms was associated with worsened perceived cognitive ability.  
Our correlational analyses also revealed that the depression subscale of the HADS was 
associated with the perceived cognitive impairment, perceived cognitive ability, and impact on 
quality of life subscales of the FACT-Cog V3. Increases in symptoms of depression was 
associated with more cognitive impairment. Additionally, the anxiety subscale of the HADS was 
associated with the impact on quality of life subscale of the FACT-Cog V3. Women with higher 
anxiety symptoms reported that their cognitive functioning had more of an impact on their 
quality of life. Finally, the perceived cognitive impairment subscale of the FACT-Cog V3 was 
associated with the perceived cognitive ability and impact on quality of life subscale of the 
FACT-Cog V3. Having less perceived cognitive impairment was associated with a higher 
perceived cognitive ability and less of an impact that cognitive functioning has on quality of life. 
See Table 5 for correlations.  
Discussion 
In conducting this research, we sought to investigate change in cognitive functioning, 
sleep quality, and mood disturbance from pre-treatment to four months following the initiation of 
treatment in a sample of newly diagnosed women with breast cancer. In doing so, we divided our 
sample into two groups; women with and without insomnia symptoms at baseline. Upon dividing 
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our sample into these groups, we assessed whether they differed at baseline in terms of their 
cognitive functioning and mood disturbance. We expected that patients would exhibit worse 
cognitive function, sleep, and mood disturbance at four months on subjective measures, and not 
on objective measures, compared to baseline. We also questioned whether change in sleep would 
be associated with subjective cognitive impairment and psychological disorders. We predicted 
that poor sleep would be associated with more subjective cognitive impairment at four months, 
as well as higher scores on measures of anxiety and depression.  
Corroborating our first hypothesis, all patients exhibited worse cognitive function, sleep, 
and mood disturbance at four months on subjective, but not objective, measures compared to 
baseline. However, women with insomnia symptoms exhibited more cognitive impairment at 
baseline compared to women that did not have insomnia symptoms. As previous research 
suggests that poor sleep is associated with cognitive decline (Gobin et al., 2015; Van Dongen et 
al., 2003), our findings may indicate that women with insomnia symptoms prior to diagnosis 
may enter treatment with worse cognition and thus be at a higher risk for further cognitive 
deterioration. Moreover, women that do not exhibit symptoms of insomnia prior to beginning 
treatment may have a buffer against a decline in cognition. Our findings are consistent with 
previous findings that women report experiencing cognitive deficits after treatment onset, as well 
as throughout the duration of treatment (Kanaskie & Loeb, 2015; Von Ah et al., 2013). However, 
these aforementioned studies did not assess pre-treatment sleep quality. Since women in such 
studies reported cognitive impairments as their biggest concerns, it is especially important to 
consider patient-reported symptoms of cognitive decline during the early stages of treatment.  
Our results also suggest that four months following the onset of treatment may be too 
early to detect changes in cognitive domains such as working memory, attention, and mental 
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control using objective measures. Previous longitudinal studies have not detected changes in 
objective cognitive functioning in patients receiving cancer treatment until at least six months 
following treatment onset (Debess et al., 2010; Quesnel et al., 2009). Studies that have detected 
specific objective deficits in cognitive domains have utilized a group comparison approach 
(patients currently undergoing treatment, post-treatment, and healthy controls), rather than a 
longitudinal approach, or have not included a pre-treatment assessment (Bender et al., 2006; 
Brezden et al., 2000; Palmer et al., 2008). Excluding a baseline assessment prevents researchers 
from knowing how patients would have performed on these measures prior to beginning 
treatment. Related, there may be pre-existing group differences in cognitive functioning. 
Additionally, patients in the cancer treatment group may have started their treatment at various 
times. Our findings support the need for longitudinal repeated assessment when assessing the 
development of symptoms such as insomnia and cognitive impairment, which may both present 
at varying times and have different individual presentations (Jansen et al., 2011; Von Ah et al., 
2013; Savard et al., 2009; Savard et al., 2011).  
Our results also strengthen previous research suggesting that women being treated for 
breast cancer experience poor sleep and are, subsequently, at an increased risk for developing 
insomnia (Savard et al., 2009; Servaes & Bleijenberg, 2002). In the present study, women 
experienced more symptoms of insomnia four months following treatment onset compared to 
pre-treatment, regardless of whether they experienced symptoms of insomnia at baseline. 
The decline in sleep quality experienced by participants in the present study is consistent 
with previous research that has detected such changes in the early stages of treatment, using 
objective measures of sleep (Savard et al., 2009). Since the present study provides evidence that 
changes in sleep during the early stages of treatment are detectable using subjective measures, it 
30 
 
should be standard to administer subjective measures of sleep such as the ISI before, during, and 
after the completion of cancer treatment. By providing patients with self-report measures of 
sleep, physicians and healthcare providers can receive immediate feedback from patients about 
their symptoms. In turn, healthcare providers can identify patients that have, or are exhibiting 
symptoms of insomnia, and intervene to refer patients to appropriate intervention to avoid further 
decline in sleep quality. By implementing therapies to avoid decline in sleep, patients may also 
be able to avoid the decline in cognitive functioning that is experienced upon beginning 
treatment.  
The present study revealed unique findings about mood disturbance in women with and 
without insomnia symptoms prior to beginning treatment. While previous research demonstrated 
an association between mood disturbance and sleep disruption after patients have begun 
treatment for cancer (Nishiura et al., 2015; Trill, 2013), we found that women experiencing 
symptoms of insomnia exhibited significantly more symptoms of depression and anxiety 
compared to women without symptoms of insomnia prior to starting treatment, and this persisted 
in the four months following the initiation of treatment. Regardless of insomnia symptom status, 
women receiving treatment for breast cancer are at risk for developing symptoms of depression 
during the early stages of treatment (Trill, 2013), but poor sleep appears to convey a greater risk. 
Since anxiety and depression have been documented as potential factors underlying a patient’s 
sleep disruption (Clevenger et al., 2013; Downie et al., 2006; Trill, 2013), it is especially 
important to monitor symptoms of mood disturbance in addition to sleep, as mood disturbance 
may be a potential risk factor for developing sleep disturbance, or vice versa. By identifying 
patients that exhibit more symptoms of anxiety and depression, health care providers can 
intervene to provide appropriate treatment/therapy procedures to decrease symptoms of mood 
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disturbance. In turn, decreasing symptoms of mood disturbance may decrease symptoms of 
insomnia experienced by patients (Clevenger et al., 2013; Downie et al., 2006; Nishiura et al., 
2013). 
Our second hypothesis was partially supported, indicating that increases in insomnia 
severity were associated with worse perceived cognitive ability. Previous research has also 
shown a relationship between sleep quality and cognitive functioning (Belenky et al., 2013; 
Gobin et al., 2015; Van Dongen et al., 2003). Other subscales included in our analysis were 
approaching significance (such as the depression subscale of the HADS and the impact on 
quality of life subscale of the FACT-Cog V3). It is possible that a relationship between changes 
in insomnia severity and depression, or the impact that cognitive dysfunction has on quality of 
life, may be detected with a larger sample. Finally, of note is the significant relationship between 
the depression subscale of the HADS and all three subscales of the FACT-Cog V3. This finding 
indicates that as symptoms of depression increase, women experience worsened cognitive 
performance.  
The current study presents many methodological strengths. First, this study provided both 
subjective and objective measures used to measure cognitive functioning and sleep, whereas 
many previous studies only included one or the other. By including both measures we were able 
to provide an objective, measurable component of cognitive function, as well as capture patient’s 
personal experience of change in cognitive functioning and sleep. Second, participants in this 
study were recruited prior to treatment initiation, whereas many previous studies did not include 
a baseline assessment in their methodology. By providing a baseline assessment, we were able to 
determine whether there were any pre-treatment differences between groups of women in our 
sample. Additionally, providing a baseline assessment allowed us to measure cognitive 
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functioning, sleep, and mood disturbance before treatment began, as well as provide indications 
as to how these factors changed during the early stages of treatment. Finally, we rigorously 
screened for other disorders that could potentially account for changes in cognition, such as 
Alzheimer’s Disease or a history of stroke.   
Despite the many strengths this study presents, it is important to acknowledge its 
potential methodological limitations. Firstly, this study includes a small sample size which could 
have negatively impacted the power to detect differences. However, even with a small sample 
size we were able to detect strong signals that cancer treatment negatively impacts sleep, 
cognition, and mood disturbance during the early stages. Secondly, our study only included four-
month follow-up data, whereas many previous studies have included assessments beyond this 
(such as eight-month, 12-month, and post-treatment follow-up). Though we were unable to 
include data beyond four months at this time, there will be eight and twelve-month data available 
in the future as the study continues.  
Despite these limitations, the findings of the present study have a number of implications 
that could potentially help women receiving treatment for breast cancer in the future. Namely, 
health care providers should screen for symptoms of insomnia, depression, and anxiety prior to 
beginning treatment, as these symptoms are highly comorbid, have a reciprocal relationship with 
each other (Clevenger et al., 2013; Savard et al., 2011; Trill, 2013), and may place patients at an 
increased risk for developing CRCD. Additionally, since our study provided evidence that 
insomnia symptoms significantly increase during the early stages of treatment, it is important for 
health care providers to consider implementing sleep therapies as early as possible to avoid a 
decline in sleep quality, and, in turn, potentially avoid decline in mood and cognitive 
functioning. Future research should examine the changes in cognition, sleep, and mood 
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disturbance with longer follow ups and investigate whether sleep quality mediates or moderates 
the relationship between cancer treatment and CRCD.
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Table 1 
Demographic Information 
 Total Sample  
(N = 32) 
No Insomnia Symptoms 
(N = 16) 
Insomnia Symptoms 
(N = 16) 
Good 
vs. Poor 
Sleepers 
 M(SD) Range M(SD) Range M(SD) Range p 
Age 59.47 (10.36) 38.00-80.00 60.00 (12.17) 38.00-80.00 58.94 (8.54) 44.00-74.00 .777 
BMI 31.06 (7.98) 16.97-51.55 29.36 (5.85) 19.13-42.93 32.76 (9.55) 16.97-51.55 .234 
# Hours worked per week 12.92 (20.30) 0-55.00 11.56 (21.03) 0-55.00 14.28 (20.13) 0-50.00 .711 
Years of Education 14.06 (4.29) 7.00-25.00 14.03 (3.88) 7.00-19.00 14.08 (4.78) 7.00-25.00 .975 
Hours of Physical Activity per week 2.68 (2.67) 0-10.00 3.14 (2.62) 0-10.00 2.48 (2.77) 0-9.50 .678 
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Table 2 
Objective Cognitive Measures 
 No Insomnia Symptoms 
M (SD) 
Insomnia Symptoms  
M (SD) 
Between  
(Group) 
Within 
(Time) 
Interaction 
(Group x 
Time) 
 Baseline 4 Months Baseline 4 Months F p F p F p 
HVLT-R           
   Immediate Recall 46.69 (8.15) 45.50 (10.16) 46.13 (9.93) 47.81 (10.28) .084 .774   .024 .877  .803 .377 
   Delayed Recall 48.44 (8.02) 44.19 (9.61) 47.06 (9.98) 47.56 (11.83)  .100 .753  1.447 .238 2.321 .138 
   Retention 51.25 (10.18) 49.88(7.08) 49.63 (9.20) 50.38(9.90)  .047 .830    .026 .874  .297 .590 
   Recognition 51.50 (6.29) 48.63 (9.60) 47.33 (10.67) 47.20 (10.74)  .923 .345    .735 .398  .611 .441 
              
LNS 11.06 (2.98) 9.94 (2.86) 10.13 (1.36)  9.88 (3.44) .363 .552  1.740 .197  .705 .408 
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Table 3  
Subjective Cognitive Measures 
Measure  No Insomnia Symptoms 
M (SD) 
 
Insomnia Symptoms  
M (SD) 
Between 
(Group) 
Within 
(Time) 
Interaction 
(Group x 
Time) 
 Baseline 4 Months Baseline 4 Months F p F p F p 
FACT-Cog V3            
   Perceived Cognitive Impairment 58.89 (11.08) 53.06 (11.08) 50.63 (11.00) 46.31 (11.83) 4.066 .053 13.089 .001   .292 .593 
   Perceived Cognitive Ability 22.88 (4.81) 19.94 (6.19) 18.88 (5.41) 17.94 (5.74) 2.918 .098   4.780 .037 1.273 .268 
   Impact on Quality of Life 14.31 (3.61) 13.69 (2.70) 10.38 (5.00) 12.75 (4.52) 5.076 .032     .863 .360 2.537 .122 
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Table 4 
Sleep Measures 
Measure Good Sleepers 
M(SD) 
Poor Sleepers 
M(SD) 
Between Within Interaction 
 Baseline 4 Months Baseline 4 Months F p F p F p 
Sleep Diaries           
   Sleep Onset Latency 20.40 (14.86) 29.53 (25.40) 34.07 (26.08) 33.80 (25.52) 1.683 .205 .772 .387 .867 .360 
   Number of Awakenings 2.17 (1.16) 2.22 (1.25) 2.59 (1.06) 2.64 (0.95) 2.684 .266 .111 .741 .001 .982 
   Minutes Awake 19.60 (16.80) 25.40 (19.69) 52.33 (35.30) 37.47 (30.10) 7.551 .010 .744 .396 3.868 .059 
   Total Sleep Time (hours) 7.45 (0.91) 7.67 (1.01) 6.57 (1.67) 7.14 (1.51) 2.720 .110 3.153 .087 .622 .437 
   Time in Bed (hours) 8.76 (0.92) 9.13 (1.18) 8.82 (1.31) 8.97 (0.93) .017 .896 1.737 .198 .289 .595 
   Sleep Efficiency (%) 85.20 (7.40) 84.00 (4.44) 73.80 (10.77) 78.93 (10.80) 7.842 .009 2.428 .130 6.295 .018 
           
ISI 3.06 (1.95) 7.69 (6.25) 13.88 (4.84) 15.38 (5.11) 44.352 .000 9.789 .004 2.548 .121 
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Table 5 
Change Score Correlations  
 ISI HADS Depression HADS Anxiety FACT-Cog PCI FACT-Cog PCA 
HADS Depression      
     r .263     
     p .080     
HADS Anxiety      
     r -.046 .301    
     p .404 .053    
FACT-Cog PCI      
     r -.181 -.460 -.006   
    p .169 .005 .488   
FACT-Cog PCA      
    r -.391 -.315 .122 .661  
    p .016 .045 .260 .000  
FACT-Cog QOL      
    R -.281 -.307 -.584 .323 .295 
    p .066 .049 .000 .041 .057 
Acronym definitions. PCI: perceived cognitive impairment, PCA: perceived cognitive ability, QOL: quality of life
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Figure 1. Baseline FACT-Cog V3 scores of participants with and without insomnia 
symptoms, *p < .05. 
 
 
Figure 2. Baseline HADS scores of participants with and without insomnia symptoms,  
*p < .05, **p < .01.
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Figure 3. FACT-Cog V3 perceived cognitive impairment subscale. both groups had 
significantly more perceived cognitive impairment four months following the initiation of 
treatment compared to baseline, p = .001. 
 
 
Figure 4. FACT-Cog V3 perceived cognitive ability subscale. Both groups perceived less 
cognitive ability four months following the start of treatment compared to baseline, p < .05.  
0
20
40
60
80
Baseline Four months
M
ea
n 
Sc
or
e
No Insomnia Symptoms Insomnia Symptoms
0
5
10
15
20
25
Baseline Four Months
M
ea
n 
Sc
or
e
No Insomnia Symptoms Insomnia Symptoms
53 
 
 
Figure 5. FACT-Cog V3 impact on quality of life subscale. Participants without insomnia 
symptoms indicated that their cognitive impairment had more of an impact on their quality 
of life compared to those with insomnia symptoms, p < .05.    
 
 
 
Figure 6. Number of minutes awake after sleep onset for participants with and without 
insomnia symptoms. Participants with insomnia symptoms spent more time awake after 
sleep onset than those without insomnia symptoms, p = .010. 
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Figure 7. Sleep efficiency (%) for participants with and without insomnia symptoms. 
Participants without insomnia symptoms had a higher sleep efficiency than those with 
insomnia symptoms, p < .010. 
 
 
  
Figure 8. ISI scores for participants with and without insomnia symptoms. Participants in 
the insomnia symptoms group exhibited more symptoms of insomnia than the group 
without insomnia symptoms, p < .001. Both groups experienced more symptoms of 
insomnia at four months compared to baseline, p < .005.  
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Figure 9. HADS depression subscale scores for participants with and without insomnia 
symptoms. Both groups experienced more symptoms of depression four months following 
the start of treatment compared to baseline, p < .01. Participants with insomnia symptoms 
exhibited more symptoms of depression than those without symptoms of insomnia, p < .05. 
 
 
Figure 10. HADS anxiety subscale scores for participants with and without insomnia 
symptoms, participants with insomnia symptoms exhibited more symptoms of anxiety 
compared to those without insomnia symptoms, p < .05.  
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